Morgan Stanley Mainz Biomed N.V. Transaction History
Morgan Stanley
- $1.27 Trillion
- Q2 2024
A detailed history of Morgan Stanley transactions in Mainz Biomed N.V. stock. As of the latest transaction made, Morgan Stanley holds 200 shares of MYNZ stock, worth $42. This represents 0.0% of its overall portfolio holdings.
Number of Shares
200
Previous 10,247
98.05%
Holding current value
$42
Previous $10,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding MYNZ
# of Institutions
10Shares Held
103KCall Options Held
0Put Options Held
0-
Northern Trust Corp Chicago, IL29.9KShares$6,2860.0% of portfolio
-
Vontobel Holding Ltd.25KShares$5,2500.0% of portfolio
-
Geode Capital Management, LLC Boston, MA15.2KShares$3,1890.0% of portfolio
-
Xtx Topco LTD London, X011.4KShares$2,3850.0% of portfolio
-
Greenwich Investment Management, Inc. Stamford, CT10.9KShares$2,2800.0% of portfolio
About MAINZ BIOMED N.V.
- Ticker MYNZ
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 14,483,000
- Market Cap $3.04M
- Description
- Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments...